207_Combined course Presentations

Alternative drugs: Bevacizumab (AVAglio)

Concurrent TMZ/RT

Adjuvant TMZ

A) CONTROL ARM

R

0

6

10 14 18 22 26 30

Weeks

921 GBM patients

R

Median PFS 10.6 vs 6.2 months

RT Alone Concurrent TMZ/RT

Adjuvant TMZ

Temozolomide 75 mg/m 2 po qd for 6 weeks, then 150–200 mg/m 2 po qd d1–5 every 28 days for 6 cycles Focal RT daily — 30 x 2 Gy Total dose 60 Gy 10 14 18 22 26 30 6 Weeks

B) EXPERIMENTAL ARM

R

0

+ Bevacizumab

RT Alone

Temozolomide 75 mg/m 2 po qd for 6 weeks, then 150–200 mg/m 2 po qd d1–5 every 28 days for 6 cycles Focal RT daily — 30 x 2 Gy Total dose 60 Gy

 The addition of Bevacizumab to TMZ-radiotherapy did not improve OS.  Improved PFS and KPS were observed with Bevacizumab  Rate of adverse events was higher with Bevacizumab (G3 related: 32% vs 15%)

Median OS 16.8 vs 16.7 months

Chinot OL. et al. NEJM 2014;370